P
Pathogen DX
Biotech & Life Sciences · Scottsdale, United States · Founded 2015
Develops a microarray based test specifically designed for the cannabis, botanical, food and agricultural testing markets MoreLess
PathogenDx, Inc. operates as a biotechnology company, providing DNA-based pathogen testing solutions designed to enhance safety across the agricultural, food, and clinical sectors. Founded in 2014 by Milan Patel, Michael Hogan, and Eric Lachance, the Scottsdale, Arizona-based firm emerged from technology developed by Dr. Hogan at Baylor Medical College and the University of Arizona. Co-founder Milan Patel, with a background in engineering and business, previously held roles at Intel and served as COO/CFO of GMSbiotech, bringing extensive experience in finance, business strategy, and life sciences. This venture was born from the realization that Dr. Hogan's DNA microarray technology had applications far beyond its original scope in clinical diagnostics for organ transplants.
The company's core offering is its proprietary Dynamic Dimensional Detection (D3 Array™) technology, a microarray-based platform for molecular testing. This system is engineered to simultaneously detect and identify up to 100 different pathogens, including bacteria, fungi, and viruses, from a single sample in approximately six hours. The technology's three-dimensional, lattice-like structure facilitates faster and more efficient binding of DNA targets, enabling rapid and sensitive results that can detect single nucleotide changes. This positions the D3 Array™ as an alternative to conventional methods like qPCR, which has limitations in multiplexing, and Next-Generation Sequencing (NGS), which can be slower and more costly.
PathogenDx operates on a razor-blade business model, selling both the consumable testing kits and the associated, non-proprietary laboratory equipment. This strategy allows laboratories to adopt the technology without significant investment in specific branded hardware. The product suite includes tailored assays for different markets, such as DetectX™, QuantX™, and EnviroX™, which are designed for compliance testing, quantification of microbial loads, and environmental monitoring, respectively. The company serves a diverse client base, including cannabis testing labs, food producers, and clinical diagnostic facilities, helping them to ensure product safety, prevent losses from contamination, and meet regulatory standards.
Keywords: pathogen detection, molecular diagnostics, microarray technology, food safety testing, agricultural testing, cannabis testing, D3 Array, DNA-based testing, multiplex PCR, microbial testing, clinical diagnostics, pathogen identification, environmental monitoring, viral detection, bacterial detection, fungal detection, genetic testing, lab testing solutions, biotechnology, public health
Talent graph
Pathogen DX's talent
Source: Dealroom Talent Intelligence.
Investors
6 investors on Pathogen DX's cap table
Sourced from Dealroom's funding and investor records.




Global footprint
Where Pathogen DX has talent and traffic
team presence
Market sentiment
What the market is saying about Pathogen DX
An AI-synthesized read of the highest-engagement posts about Pathogen DX on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Pathogen DX on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.